NCT04986852 - Olinvacimab With Pembrolizumab in Patients With mTNBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

February 28, 2025

Study Completion Date

August 30, 2026

Conditions

Metastatic Triple-Negative Breast Cancer

Interventions

DRUG

Olinvacimab

Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).

Trial Locations (1)

6009

RECRUITING

Hollywood Private Hospital, Nedlands